Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 134

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 134
---
 credit risk, NewGenIvf
compares the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition.
It considers available reasonable and supportive forwarding-looking information, such as GDP growth rate and nominal GDP per capita.
Based on the impairment assessment performed by NewGenIvf, the directors considered the loss allowance for account receivables as of
December 31, 2023 and December 31, 2024 is $19 and $19, respectively.

Cash and cash equivalents

NewGenIvf is exposed to concentration
of credit risk on liquid funds which are deposited with several banks with high credit ratings. The credit risk on liquid funds is limited
because the counterparties are banks with high credit ratings assigned by international credit-rating agencies.

Deposits and other receivables, amount due from shareholders and loan to A SPAC I

NewGenIvf assessed the impairment
for deposits and other receivables, due from shareholders and loan to A SPAC I individually based on internal credit rating and ageing
of these debtors which, in the opinion of the directors, have no significant increase in credit risk since initial recognition. Based
on the impairment assessment performed by the Company, the directors consider the loss allowance for deposits and other receivables and
due from shareholders as of December 31, 2024 was US$4 and Nil respectively. The loss allowance for deposits and other receivables, and
due from shareholders and loan to A SPAC I as of December 31, 2023 is $14, $17,818 and Nil, respectively.

Cash flow interest rate risk

NewGenIvf is exposed to cash
flow interest rate risk through the changes in interest rates related mainly to its variable-rates bank balances.

NewGenIvf currently does
not have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest rate risk. The directors
monitor NewGenIvf’s exposures on an ongoing basis and will consider hedging the interest rate should the need arises.

<div align='center'>75</div>

Sensitivity analysis

The sensitivity analysis
below has been determined by assuming that a change in interest rates had occurred at the end of the reporting period and had been applied
to the exposure to interest rates for financial instruments in existence at that date. 1% increase or decrease is used when reporting
interest rate risk internally to key management personnel and represents management’s assessment of the